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Abstract
Current treatment for advanced stage ovarian clear cell cancer is severely hampered by a lack of effective systemic therapy
options, leading to a poor outlook for these patients. Sequencing studies revealed that ARID1A is mutated in over 50% of
ovarian clear cell carcinomas. To search for a rational approach to target ovarian clear cell cancers with ARID1A mutations,
we performed kinome-centered lethality screens in a large panel of ovarian clear cell carcinoma cell lines. Using the largest
OCCC cell line panel established to date, we show here that BRD2 inhibition is predominantly lethal in ARID1A mutated
ovarian clear cell cancer cells. Importantly, small molecule inhibitors of the BET (bromodomain and extra terminal domain)
family of proteins, to which BRD2 belongs, speciﬁcally inhibit proliferation of ARID1A mutated cell lines, both in vitro and
in ovarian clear cell cancer xenografts and patient-derived xenograft models. BET inhibitors cause a reduction in the
expression of multiple SWI/SNF members including ARID1B, providing a potential explanation for the observed lethal
interaction with ARID1A loss. Our data indicate that BET inhibition may represent a novel treatment strategy for a subset of
ARID1A mutated ovarian clear cell carcinomas.
Introduction
Epithelial ovarian cancer covers approximately 90% of all
ovarian cancers and is the most common cause of mortality
in women with gynecologic cancers. Five histological
subtypes have been deﬁned for epithelial ovarian cancers:
high-grade serous, low-grade serous, clear cell, mucinous,
and endometrioid [1, 2]. Although each subtype has unique
molecular and clinical features, all epithelial ovarian sub-
types are still treated similarly, consisting of de-bulking
surgery in combination with platinum-based chemotherapy.
Ovarian clear cell carcinoma (OCCC), the second most
common subtype, appears to have a worse prognosis than
the more common high-grade serous carcinoma, suggesting
that current treatments are ineffective for OCCC, especially
related to a poor response to platinum-based chemotherapy.
Therefore, new treatment strategies for OCCC are urgently
needed [3]. Development of OCCC has been linked to
endometriosis and is characterized by a high mutation fre-
quency of ARID1A (>50%), a subunit of the SWI/SNF
chromatin remodeling complex [4, 5]. Given the nature of
the mutations it is generally accepted that ARID1A func-
tions as a tumor suppressor gene. The SWI/SNF chromatin-






1 Division of Molecular Carcinogenesis and Oncode Institute, The
Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066
CX, The Netherlands
2 Gynaecologic Oncology, Cancer Research Centre Groningen,
University Medical Center Groningen, University of Groningen,
Hanzeplein 1, Groningen 9713 GZ, The Netherlands
3 Department of Obstetrics and Gynaecology, Iwate Medical
University School of Medicine, Iwate, Morioka 020-8505, Japan
4 Medical Oncology, Cancer Research Centre Groningen,
University Medical Center Groningen, University of Groningen,
Hanzeplein 1, Groningen 9713 GZ, The Netherlands
Electronic supplementary material The online version of this article
(https://doi.org/10.1038/s41388-018-0300-6) contains supplementary















remodeling complex regulates the dynamic repositioning of
nucleosomes, therefore the loss of ARID1A could globally
impact gene expression through deregulated transcription
[6]. Since ARID1A mutations have been identiﬁed in pre-
neoplastic lesions it is suspected that ARID1A loss is an
early event in the development of OCCC [4]. Possibly, loss
of ARID1A activates major signaling pathways that confer
an advantage to the tumor cells through enhanced
Fig. 1 TRC kinome screen in OCCC cell panel. a ARID1A protein
expression levels of the OCCC panel were measured by Western blot
analysis. HSP90 was used as a loading control. b Each cell line from
the OCCC panel was infected in triplicate with the lentiviral TRC
kinome library with a multiplicity of infection below 0.5 and with cell
amounts ensuring 1000× coverage of the library. Upon stable selection
of the library timepoint zero (T0) was collected, followed by culturing
of the cells for an additional two weeks, after which timepoint one (T1)
was harvested. The relative abundance of the hairpins in T0 versus T1
was determined by deep sequencing. c Ranked lists for the lethal
kinases were generated for every OCCC line based on three criteria
(fold depletion, Geometric mean value of all hairpins and Second-best
gene rank according to RIGER) as outlined in the methods section.
From these ranked hit lists we determined which genes were lethal
upon knockdown in all cell lines (common lethal hits) or preferentially
in the ARID1A mutant lines (ARID1A speciﬁc lethal hits) and a top 5 is
shown
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proliferation and/or survival. Given that ARID1A is inacti-
vated by mutation in OCCC, we pursued a synthetic lethal
screening strategy to identify druggable targets in OCCC.
We performed lethal kinome short hairpin (shRNA) screens
in the largest panel of OCCC cell lines established to date
having different ARID1A mutation status. Here, we report
the identiﬁcation of BRD2, a member of the BET (bromo-
domain and extra terminal domain) family, whose
ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors 4613
knockdown resulted in enhanced toxicity predominantly in
ARID1A mutant cell lines. Importantly, our data demon-
strate enhanced sensitivity of ARID1A mutated cells to the
BET inhibitors JQ1 and iBET-762. Furthermore, the in vitro
drug sensitivity data presented here were validated both in
OCCC cell line xenografts and in OCCC patient-derived
xenograft (PDX) models. Collectively, our data suggest a
new treatment option for ARID1A mutant OCCC that war-
rants clinical exploration.
Results
ARID1A synthetic lethal screens in OCCC cell line
panel
To investigate which vulnerabilities exist in ARID1A mutant
OCCC lines we collected a very sizeable and unique set of
OCCC cell lines and validated their ARID1A status by both
ARID1A sequencing and ARID1A protein expression ana-
lysis. We screened in total 14 OCCC cell lines (5 ARID1A
wildtype and 9 ARID1A mutant, Fig. 1a) with a lentiviral
shRNA library covering the human kinome to search for
kinases whose suppression is speciﬁcally lethal in an
ARID1A mutant context. We have previously described
kinome-centered screening approaches using this library [7,
8]. In short, each cell line was infected with the kinome
shRNA library in triplicate, selected for presence of viral
integration, cells were harvested at timepoint zero (T0) and
the remainder was replated and cultured. After two to three
weeks, cells were collected for timepoint one (T1). Genomic
DNA was isolated from both populations, and the relative
abundance of the short hairpin sequences was determined
by deep sequencing (Fig. 1b). For the selection of synthetic
lethal genes, we set several criteria to ensure identiﬁcation
of hits with signiﬁcant toxicity and with multiple hairpins
(see Methods). Following these criteria, we generated
ranked lists for the lethal kinases per cell line (Figure S1 and
S2). By analyzing these cell-speciﬁc ranked lists we could
identify common lethal kinases (PLK1, CHEK1, CDC2L1,
TRRAP, and TAF1) and kinases that were more often lethal
in the ARID1A mutant cell lines (BRD2, PRPF4B, MYO3B,
PKN1, and PRKCQ) (Fig. 1c). The lethal kinases that were
exclusively selected in the ARID1A mutant lines (BRD2 and
PRPF4B) were further validated. We subsequently
observed that PRP4FB loss was lethal in all the OCCC cell
lines tested (data not shown), so toxicity appeared inde-
pendent of ARID1A mutation status. Interestingly, BRD2
depletion using two independent shRNA sequences (vali-
dated on protein levels Figure S3A) recapitulated the
screening data more convincingly (Fig. 2a, Figure S3B).
Especially in those ARID1A mutant lines where BRD2 was
previously identiﬁed as lethal hit (TOV21G, OVTOKO,
HAC2, SMOV2, and OVMANA), signiﬁcant killing with
two shBRD2 constructs was observed (with one shBRD2
resulting in at least 70% cell number reduction) and BRD2
was therefore considered as the only hit from our ARID1A
synthetic-lethal screens. Validation of BRD2 depletion in
the complete OCCC panel identiﬁed the cell line RMGI as
one notable outlier, as BRD2 knockdown appeared to be
toxic in this cell line whereas BRD2 was not identiﬁed as a
lethal hit in the RMGI screen. Possibly, during validation
BRD2 shRNAs were introduced at higher titer compared to
screening conditions leading to better knockdown and
toxicity during validation procedure. Of note, we identiﬁed
comparable BRD2 and BRD4 protein and RNA levels
across the OCCC cell line panel indicating that different
sensitivities towards BRD2 knockdown cannot be explained
by the BRD2 and BRD4 status of the individual cell line
(Figure S4A, B, C).
BET domain inhibition speciﬁcally inhibits the
proliferation of ARID1A mutant OCCC lines
To further validate whether BRD2 depletion caused pro-
liferation defects predominantly in an ARID1A mutant
context, we targeted BRD2 function with the use of BET
inhibitors. Selective inhibitors targeting BET proteins
BRD2, BRD3, BRD4 as well as BRDT, have been descri-
bed to exhibit antineoplastic activity [9]. BET inhibitors are
currently in clinical trials for various hematological malig-
nancies and solid tumors. BET inhibitors bind to acetylated
lysine recognition motifs on the thereby preventing binding
of BET proteins to the chromatin, resulting in disruption of
subsequent chromatin remodeling and gene expression [10].
First, we tested the BET inhibitor JQ1 on our OCCC panel
using a long-term proliferation assay. Interestingly,
JQ1 sensitivity closely matched the BRD2 knockdown
Fig. 2 BRD2 validates as ARID1A mutant speciﬁc lethal hit. a The
functional phenotypes of non-overlapping lentiviral shBRD2 vectors
(#2 and #5) in the OCCC cell line panel were measured in a long-term
colony formation assay. Cells expressing a mixture of nonfunctional
scrambled hairpins (SCR) were used as control. The cells were ﬁxed,
stained and photographed after 10–12 days. In the cell lines labeled
with an asterisk (*) BRD2 was identiﬁed as lethal hit. b The indicated
ARID1A wildtype and mutant OCCC cell lines were plated in 6-well
plates (10,000 cells per well) and exposed to increasing JQ1 (0, 125,
250, and 500 nM) concentrations in triplicate. The cells were ﬁxed,
stained with crystal violet and photographed after 10 days. c Colony
formation assays (CFA) from b were quantiﬁed by crystal violet dye
extraction. Shown is relative reduction in crystal violet staining
compared to untreated control. Colony formation assays were per-
formed in triplicate. Error bars denote SD. The dotted line denotes the
cut-off used (below 0.5 at 250 nM JQ1 concentration) to qualify cell
lines as “JQ1 sensitive”. A Fisher Exact test with the abovementioned
cutoff at 250 nM JQ1 gave the statistic value of 0.09. P-values (only
shown for the “JQ1 sensitive” lines) were calculated with multiple t-
tests, asterisk denote the number of digits after the decimal
4614 K. Berns et al.
lethality across the OCCC cell line panel (Fig. 2a, b). Thus,
ARID1A mutant cells appear more sensitive to BET inhi-
bition than ARID1A wildtype cell lines. From the JQ1
colony formation assays we conclude that, based on a cutoff
of 50% growth reduction at 250 nM JQ1, 1 out of 5 ARID1A
wildtype cell lines and 7 out of 9 ARID1A mutant cell lines
are sensitive to the BET inhibitor (Fig. 2c). Collectively,
these ﬁndings demonstrate that BRD2 knockdown lethality
closely resembles JQ1 sensitivity in OCCC lines, and that
ARID1A mutant lines are most sensitive to BET inhibition.
ARID1A depletion enhances sensitivity to JQ1
The genetic heterogeneity of the OCCC cell line panel
poses a possible limitation in determining a genotype-
speciﬁc toxicity. To ﬁrmly establish ARID1A mutation as a
direct cause of enhanced BET inhibitor sensitivity, we
chose to test our ﬁndings further in OCCC isogenic cell line
pairs. For this, we generated ARID1A knockout subclones
from the ARID1A wildtype cell lines ES2 and OVCA429
using CRISPR/Cas9 targeting. In both a polyclonal ES2 cell
line having signiﬁcant ARID1A reduction as well as a full
knockout ES2 single cell clone, we observed that loss of
ARID1A signiﬁcantly sensitized to BET inhibition by JQ1
(Fig. 3a, b). Similarly, the ARID1A knockout
OVCA429 subclones acquired enhanced sensitivity to JQ1
inhibition (Fig. 3c, d). These ﬁndings demonstrate a direct
causal link between loss of ARID1A function and sensi-
tivity towards BET inhibitors. We noted that the ARID1A
knockout clones adapted upon prolonged culturing (within
months) in such a way that they gradually lost their
enhanced sensitivity towards JQ1 inhibition (data not
shown). This gradual adaptation to a drug-tolerant state has
been observed before in other cell models [11]. Although
speculative, we hypothesize that tumor-derived ARID1A
mutant OCCC lines may have acquired additional genetic
alterations causing a more stable phenotype compared to
cell lines generated by CRISPR/Cas9 mediated ARID1A
manipulation.
JQ1 and iBET762 have similar activity in ARID1A
deﬁcient OCCC lines
To further validate our ﬁndings, we tested another BET
inhibitor, iBET762. First, we compared the inhibitors JQ1
and iBET762 in a long-term proliferation assay in two
ARID1A wildtype (ES2 and OVCA429) and two ARID1A
mutant (SMOV2 and HAC2) OCCC lines. The ARID1A
mutation dependent toxicity of BET inhibition appeared
extremely similar for JQ1 and iBET762 in these cell lines
(Fig. 3e, f). Next, iBET762 was tested on both ES2 (Fig. 3g)
and OVCA429 (Fig. 3h) wildtype and ARID1A knockdown
clones. Knockdown efﬁciencies for two independent
shARID1A constructs were checked at the protein level (Fig.
3i, j). Upon ARID1A knockdown, both OCCC lines dis-
played increased iBET762 lethality in these experiments
(Fig. 3g, h). Collectively, we conclude that BET inhibition
by the addition of either JQ1 or iBET762 is more toxic in
ARID1A mutant lines, further validating our BRD2 screen
hit.
BET inhibition directly downregulates ARID1B
expression
We next sought to investigate why ARID1A deﬁcient cells
exhibit an enhanced sensitivity towards BET inhibition.
BET inhibitors likely exert a broad effect on transcription.
A recent study identiﬁed ARID1B, a SWI/SNF member
mutually exclusive with ARID1A in this complex, as a gene
critically required for the survival of ARID1A mutant cell
lines [12]. Based on this we tested whether BET inhibition
had an impact on ARID1B expression. First, we tested the
effect of increasing amounts of JQ1 on ARID1B expression
in the OVCA429 ARID1A wildtype and knockout cell lines.
The differential sensitivity of these isogenic lines towards
JQ1 was already demonstrated in Fig. 3. We indeed
observed a concentration-dependent downregulation of
ARID1B expression both at RNA (Fig. 4a) and protein
levels (Fig. 4b). MYC protein levels were included as a
positive control for effective inhibition. Similar results were
obtained in the ES2 ARID1A wildtype and knockout cell
lines (data not shown). Second, we observed that BRD2
knockdown resulted in reduced ARID1B protein levels,
directly implicating BRD2 in the regulation of ARID1B
expression (Fig. 4c). Moreover, after knockdown of
ARID1B expression in several OCCC lines, we observed
toxicity only in an ARID1A mutant background, in agree-
ment with earlier published experiments (Fig. 4d, e). Of
note, when testing the ARID1A mutant lines in which BRD2
was not identiﬁed as a hit (KOC7C, OVAS, RMGII and
TUOC1), we observed signiﬁcant toxicity of ARID1B
knockdown in those lines that also displayed signiﬁcant
BETi toxicity (OVAS, RMGII, and TUOC1), suggesting
that BRD2 was probably not identiﬁed as a hit due to our
hit-selection criteria or technical variations during screening
procedures (Figure S4D,E). We noted that exogenous
ARID1B overexpression could not rescue JQ1 mediated
growth inhibition (data not shown) suggesting that multiple
factors may be involved in JQ1 mediated cell toxicity. In
accordance with previous studies [13], we noticed sig-
niﬁcant toxicity upon ARID1B overexpression, which
complicated these rescue experiments considerably. Col-
lectively, our ﬁndings suggest that down-modulation of
ARID1B by BET inhibitors contribute to the ARID1A
mutant speciﬁc vulnerability in OCCC cell lines, but likely
is not solely responsible for the observed growth defects.
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BET domain inhibition inhibits expression of other
SWI/SNF members
When analyzing RNAseq data from OVCA429 ARID1A
wildtype and knockout cells exposed to JQ1, we observed
that BET inhibition resulted in transcriptional repression of
several SWI/SNF family members besides ARID1B,
including SMARCC2 and SMARCE1 (data not shown). As
such, BET inhibition may interfere with SWI/SNF function
by affecting the transcription of multiple components of this
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multi-protein complex. To examine the generality of this
observation we tested the effect of JQ1 exposure on gene
expression of the SWI/SNF members ARID1B, SMARCC2
and SMARCE1 in the complete OCCC panel. MYC was
taken along as a control. Indeed, JQ1 treatment of the
complete OCCC cell line panel resulted in a robust down-
regulation of the indicated SWI/SNF RNA levels, demon-
strating a general effect of BET inhibition on the gene
expression of SWI/SNF members (Fig. 5a, b). Notably,
MYC RNA levels were downregulated by JQ1 exposure
only in a subset of OCCC cell lines, suggesting that MYC
repression by bromodomain inhibition is not a general
phenomenon in OCCC cell lines.
Interestingly, chromatin immunoprecipitation experi-
ments demonstrated speciﬁc BRD2 binding to various SWI/
SNF member promoter regions, including ARID1A,
ARID1B, SMARCE1, and SMARCC2, both in ARID1A
wildtype (OVCA429) and ARID1A mutant (HAC2) cell
lines (Fig. 6a). Furthermore, JQ1 treatment efﬁciently
inhibited BRD2 chromatin binding in OVCA429 and
HAC2 (Fig. 6b, c, Figure S5). The BRD2 ChIP sequencing
data were veriﬁed by qPCR of the ARID1B promoter region
(Fig. 6d). Of note, in this experiment we also included a
BRD4 ChIP and observed no binding of BRD4 to the same
ARID1B promoter region (Fig. 6e). These observations
suggest that the effects of BRD2 inhibition on ARID1B
expression and other SWI/SNF members are speciﬁc and
direct.
In vivo OCCC models demonstrate ARID1A
dependent sensitivity to JQ1
To test the ARID1A dependent sensitivity towards BET
inhibition in vivo, we used NSG mice xenografted with
OCCC cell lines. Unfortunately, engraftment efﬁciency of
OCCC cells appeared rather low since from the tested ES2,
SMOV2, TUOC1, and HAC2 cell lines, only ES2 and
SMOV2 grew in mice. For the ARID1A wildtype ES2
xenograft cohorts, we did not observe a signiﬁcant growth
difference between the vehicle and JQ1 treated tumors (Fig.
7a). In contrast, the ARID1A mutant SMOV2 xenografts
were signiﬁcantly growth impaired upon JQ1 treatment
(Fig. 7b). In agreement with this, the tumor weights of
excised tumors were not signiﬁcantly reduced in JQ1 treated
ES2 xenografts (Fig. 7c) but signiﬁcantly declined in the
JQ1 treated SMOV2 xenografts (Fig. 7d). Furthermore,
Western blot analysis of SMOV2 tumor lysates demon-
strated a signiﬁcant reduction of ARID1B expression upon
JQ1 treatment compared to DMSO vehicle control (Figure
S6A). Thus, upon prolonged exposure in an in vivo model,
BET inhibition downregulates ARID1B, likely contributing
to the enhanced sensitivity of these tumor xenografts to
JQ1. Given the low engraftment efﬁciencies of the OCCC
cell lines, we reasoned that OCCC PDX models could
provide an alternative strategy to further validate our results
in vivo. F3 tumor pieces from an ARID1A wildtype and an
ARID1A mutant (homozygous ARID1A 1148* stop-gained
mutation) PDX model (Figure S6B), were subcutaneously
implanted in NSG mice, and were randomized into vehicle
control and JQ1 treatment groups. For the PDX-ARID1A-
wildtype cohort, JQ1 treatment did not signiﬁcantly impair
tumor growth compared to vehicle control treatment (Fig.
7e). Importantly, tumor growth in the PDX-ARID1A-mutant
cohort was greatly impaired by JQ1 treatment (Fig. 7f).
Thus, in agreement with the OCCC cell line xenograft
experiments, ARID1A mutant PDX tumors are sensitive to
JQ1, whereas ARID1A wildtype PDX tumors are unaffected
by JQ1 treatment. Of note, Ki67 staining was stronger
reduced upon JQ1 treatment in the ARID1A mutant PDX
tumors, whereas Cleaved Caspase3 staining of the JQ1
treated tumors revealed a small but signiﬁcant increase in
apoptotic cells in the ARID1A mutant PDX tumors (Figure
S6C, D). Collectively, these observations support the notion
that BET inhibitors are potentially useful for the treatment
of ARID1A mutant OCCC.
Discussion
Through loss of function genetic screens in a large panel of
OCCC cell lines, we identify BRD2 loss as an ARID1A
mutation-speciﬁc dependency in OCCC cell lines. BRD2 is
Fig. 3 ARID1A loss induces sensitivity towards BET inhibitors. a, c
ES2 and OVCA429 ARID1A knockout cell lines were generated
with a dual vector doxycycline inducible CRISPR/Cas9 vector
system. For ES2, wildtype (wt) cells, one polyclonal knockout line
(ARID1A kopc) and one monoclonal knockout line (ARID1A ko#2)
and for OVCA429, wt cells and two monoclonal knockout lines
(ARID1A ko#12 and #37) were tested for JQ1 sensitivity in a 384
well 6-day cell viability assay using CellTiter Blue (CTB) as a
readout. CTB measurements were normalized to untreated controls.
Error bars denote SD. P-values were calculated with 2-way
ANOVA, asterisk denote the number of digits after the decimal. b,
d ARID1A Western blot analysis of ARID1A protein levels in the
ES2 polyclonal ARID1A knockout clone and ES2/OVCA429
monoclonal ARID1A knockout clones. e, f The indicated two
ARID1A wildtype and ARID1A mutant lines were exposed to
increasing doses of BET inhibitors JQ1 and iBET762. After
10–12 days cells were stained and photographed. g, h ES2 and
OVCA429 cell lines were stably infected with the indicated shRNA
constructs targeting ARID1A and plated in 384 well plates. Con-
ﬂuency was monitored in the absence and presence of the BET
inhibitor iBET762 (800 nM). Shown are Incucyte conﬂuency mea-
surements relative to untreated cells from three independent
experiments. Error bars denote SD. P-values were calculated with
multiple t-tests, asterisk denote the number of digits after the deci-
mal. i, j Western blots were performed on the ES2 and OVCA429
cell lines stably infected with the indicated shARID1A constructs to
monitor efﬁciency of ARID1A knockdown. HSP90 served as a
loading control
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a member of the BET family of proteins consisting of
BRD2, BRD3, BRD4, and BRDT. Bromodomain proteins
are epigenetic readers, that play a role in transcriptional
regulation through binding of hyperacetylated chromatin.
BET proteins have also been reported to act as protein
kinases, explaining their presence in the kinome library
[14]. Importantly, inhibiting BRD2 function resulted in
enhanced sensitivity of the ARID1A mutant OCCC lines. Of
note, BRD4 loss appeared to be toxic in various OCCC lines
independent of ARID1A status, whereas BRD3 and BRDT
were not selected as lethal hits in our screens (Figs. S1,2).
Presumably, the BET family members exert diverse and
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only partially overlapping functions in OCCC cell lines
causing only loss of the BET member BRD2 to be synthetic
lethal with ARID1A mutation. In line with this assumption,
a recent study reported a very different genome-wide
occupancy of BRD2 and BRD4, suggesting non-redundant
genomic functions [15]. Our observation that speciﬁcally
BRD2, and not BRD4, binds to the ARID1B promoter
region suggests that BRD2 knockdown may have different
effects on residual SWI/SNF function in ARID1A mutant
OCCC lines than BRD4 knockdown. Furthermore, gene
essentiality data generated for luminal breast cancer cell
lines recently uncovered a BET-independent requirement
for BRD4, demonstrating that BRD4 knockdown lethality
not always coincides with JQ1 sensitivity [16]. Indeed, also
in our OCCC cell lines BRD4 knockdown lethality could
not predict JQ1 response. However, more detailed infor-
mation on the inhibitory efﬁciencies of both JQ1 and
iBET762 on the different bromodomain family members in
OCCC lines will be required to support this hypothesis.
Interestingly, we show that ARID1A depletion directly
sensitized OCCC lines to BET inhibition, further strength-
ening the notion that ARID1A loss is critical to the observed
phenotype. Currently, we have no indications that ARID1A
loss sensitizes other cancer types to BET inhibition, sug-
gesting an OCCC-speciﬁc context dependency for the
ﬁndings we report here.
Our data suggest that ARID1B transcriptional down-
modulation by BET inhibition contributes to the ARID1A
mutant dependent toxicity. However, we cannot rule out
that other (SWI/SNF) factors regulated by members of the
BET domain family contribute to the observed phenotypes.
It has been stated previously that ARID1B may be a
potential therapeutic target for ARID1A mutant cancers [12].
Importantly, we here demonstrate that BET inhibition may
provide a way to target ARID1B indirectly, which could be
explored further therapeutically. In that light, it is
encouraging that the ARID1A dependent sensitivity to BET
inhibitors was also observed in OCCC xenografted mice
treated with the BET inhibitor JQ1. Unfortunately, more
extensive in vivo cell line validation experiments were
complicated by the low tumor-take rate of xenografted
OCCC cell lines. Therefore, the OCCC PDX experiments
reported here provide important additional evidence that
BET inhibition imposes an ARID1A mutant dependent
toxicity in an in vivo model.
It has been reported that inhibition of the methyl-
transferase EZH2 may represent a novel treatment strategy
for ARID1A mutant cancers [17]. Furthermore, recent stu-
dies have demonstrated a speciﬁc sensitivity of ARID1A
mutant OCCC cells to either dasatinib [18] or to the
HDAC6 inhibitor ACY1215 [19]. For future studies it will
be of interest to test these different synthetic lethal inter-
actions together with our present ﬁndings to compare their
ability to speciﬁcally target ARID1A mutant OCCC in vivo.
Of note, the OCCC cell line panel used in our study to
search for ARID1A mutation dependency is the largest
reported to date, thereby most closely reﬂecting the muta-
tion spectrum (e.g., concurrent hotspot mutations in
PIK3CA, KRAS) found in OCCC patients [20]. As might be
expected from such a heterogeneous group of cell lines,
there was not a perfect separation between ARID1A mutant
and wildtype cell lines in terms of BET inhibitor response.
However, we believe that the remarkable sensitivity of the
majority of ARID1A mutant OCCC lines for the BET
inhibitors warrants further (pre)-clinical exploration.
In summary, we report here an unexpected and new
synthetic lethal interaction between BRD2 loss and ARID1A
mutation. We suggest that the inhibitory effects on residual
SWI/SNF function, speciﬁcally via reduced ARID1B
expression, may explain the enhanced sensitivity of
ARID1A mutant cells to BET inhibitors. Our data imply that
patients with ARID1A mutant OCCC may beneﬁt from BET
domain inhibitors added to their treatment regimen.
Materials and methods
OCCC cell lines and genotyping
TOV21G was obtained from ATCC; OVTOKO, RMGI,
RMGII, OVMANA, HAC2 from JCRB Cell Bank; JHOC5
from RIKEN Cell Bank; OVCA429 from Cell Biolabs;
TUOC1, OVAS, SMOV2, and KOC7C were kindly pro-
vided by Hiroaki Itamochi; ES2 was a kind gift from Els
Fig. 4 BET inhibition reduces ARID1B levels. a OVCA429 ARID1A
knockout cell lines were generated with a dual vector doxycycline
inducible CRISPR/Cas9 vector system. Wildtype cells, one polyclonal
knockout line (ARID1A kopc) and two monoclonal knockout lines
(ARID1A ko#12 and #37) were exposed to increasing amounts of JQ1
as indicated. After 48 h drug exposure ARID1B RNA analysis was
performed. mRNA levels were normalized to expression of GAPDH.
Error bars denote SD. P-values were calculated with multiple t-tests,
asterisk denote the number of digits after the decimal. b The
OVCA429 cells described in a were subjected to Western blot analysis
for the indicated proteins. ACTIN served as a loading control. c
Western blot analysis of ARID1B and BRD2 in OVCA429 cells stably
infected with lentiviral shRNA vectors targeting BRD2. ACTIN served
as a loading control. d Doxycycline inducible lentiviral ARID1B
shRNA vectors #3 and #5 were introduced in two ARID1A wildtype
and two ARID1A mutant OCCC lines. After stable selection cells were
plated in a long-term proliferation assay in the presence of doxycy-
cline. Cells expressing a mixture of nonfunctional scrambled hairpins
(SCR) were used as control. The cells were ﬁxed, stained and pho-
tographed after 10–14 days. e ARID1B mRNA expression analysis by
qRT-PCR in ES2, OVCA429, SMOV2 and HAC2 cells stably
expressing the two doxycycline-inducible shARID1B vectors. mRNA
levels were normalized to expression of GAPDH. Error bars denote
SD. P-values were calculated with multiple t-tests, asterisk denote the
number of digits after the decimal
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Berns and OV207 was a kind gift from Vijayalakshmi
Shridhar. All cells were maintained in RPMI supplemented
with 10% Fetal Calf Serum and 100 µg/ml Penicilin/Strep-
tomycin and 2 mM L-Glutamine and tested negative for
mycoplasma contamination. The Haloplex sequencing
custom platform from Agilent was used to determine
ARID1A mutation status, with the target region design based
on NM_139135 and NM_006015. OCCC cells were clas-
siﬁed as “ARID1A mutant” when homozygous frameshift
and/ or nonsense ARID1A mutations were detected in
combination with no detectable ARID1A protein on
Western.
TRC kinome screen
A kinome-centered short hairpin RNA (shRNA) library tar-
geting 535 human kinases was assembled from the TRC
human genome-wide shRNA collection (TRCHs1.0). Each
OCCC line was stably transduced by lentiviral infection in
triplicate with a multiplicity of infection (MOI) below 0.5 and
sufﬁcient number of cells to ensure a 1000-fold library cov-
erage. A T0 time point sample was taken from the cells stably
expressing the shRNA library and the remainder of the cells
was cultured for 2–3 weeks after which T1 was harvested.
The relative abundance of each shRNA comparing T1 to T0
was determined using the R/Bioconductor package DESeq
[21]. Kinases were considered as lethal hits when the P value
calculated using DESeq was lower than 0.1 and the following
three criteria were fulﬁlled: (1) at least one hairpin with a Fold
Change below 0.3 (to ensure signiﬁcant toxicity), (2) a geo-
metric mean of all the hairpins below 0.8 (to ensure that the
majority of hairpins have a similar effect, reducing false-
positive results), (3) a top 100 ranking according to the Sec-
ond Best Gene Rank in RIGER (a method to rank genes by
the rank of the second best scoring hairpin of that gene,
ensuring selection of genes with at least two functional hair-
pins) [22]. The DESeq screening data for the 14 OCCC lines
are enlisted in Supplementary Data ﬁle S1.
Fig. 5 BET inhibitors target multiple SWI/SNF members. a, b
ARID1A wildtype (a) and ARID1A mutant (b) OCCC lines were
exposed for 40 h to 500 nM JQ1 and were subjected to mRNA
expression analysis with qRT-PCR. mRNA levels were normalized to
expression of GAPDH and displayed is the relative expression of the
indicated mRNAs to untreated cells. Error bars denote SD
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Plasmids
The following TRC pLKO.1 shRNA vectors were used for
validation: BRD2#2: TRCN0000006309; BRD2#5:
TRCN0000006312. The lentiviral vector pLKO.1-Scramble
shRNA was obtained from Addgene (#1864). A doxycy-
cline inducible lentiviral shRNA vector (GINSENG) [23]
was modiﬁed as described [24] and was used to express the
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ARID1B hairpins (#3: GGAAGATTAGAGGGTCACATA
and #5: GCCGAATTACAAACGCCATAT) under the
control of doxycycline. ARID1A knockout cell lines were
generated with a dual vector doxycycline inducible
CRISPR/Cas9 vector system (iKRUNC) as described [25]
using the gRNA sequence targeting ARID1A: AGGAT-
GAGTCACGCCTCCAT. pLKO was used to express the





For Western blotting primary antibodies against ARID1A
(PSG3), ACTIN (C2), HSP90 (H-114), CMYC (N-262),
BRD4 (H-250) were obtained from Santa Cruz Bio-
technology; BRD2 (A302-582A) from Bethyl; ARID1B
(AB57461) and Histone-H3(trimethylK27) (AB6002) from
Abcam. Immunohistochemical analysis of parafﬁn-
embedded xenograft slices were performed as described
[26], using antibodies against Cleaved-Caspase3 from Cell
Signaling (#9661); Ki67 from DAKO (M7240) and
ARID1A from Sigma (HPA005456). iBET762 was
obtained from Xcess Biosciences. JQ1 for the cell line
experiments was kindly provided by the Bradner lab (Dana-
Farber Cancer Institute, Boston, USA) [9] and later pur-
chased from Axon Medchem (axon 1989); both batches had
similar activity. JQ1 (HY-13030) used in the xenograft
experiments was purchased from MedChem Express.
Before use in animals, the in vitro activity of JQ1 (HY-
13030) was compared to the activity of JQ1 obtained from
Axon Medchem.
Quantitative RT-PCR
The 7500 Fast Real-Time PCR System from Applied Bio-
systems was used to measure mRNA levels which were
normalized to expression of GAPDH. Each QRT-PCR
experiment included technical replicates and were repeated
at least once. The following primer sequences were used in
















For long-term colony formation assays, cells were cultured in
6-well plates and medium was refreshed every 3 days. After
10 days cells were ﬁxed with 4% formaldehyde and stained
with 0.1% crystal violet and subsequently scanned. Colony
formation assay quantiﬁcation was performed by optical
density measurements of extracted dye at 590 nM. Prolifera-
tion assays were repeated at least three times, within one assay
three technical replicates were performed. Representative
stainings and quantiﬁcations are shown. Six-day growth
assays were performed in quadruple in 384-well plates and
were quantiﬁed with the cell viability assay CellTiter-Blue
(Promega) or by conﬂuency monitoring in an IncuCyte Zoom
live cell imaging system (Essen BioScience). Measurements
were normalized to untreated controls.
Chromatin immunoprecipitation
Chromatin Immunoprecipitation (ChIP) was performed as
described [27]. For each ChIP 4 µg anti-BRD2 (A302-583A)
or anti-BRD4 (A301-985A) from Bethyl Laboratories and
control Rabbit IgG SC-2027 from Santa Cruz Biotechnology
were used. ChIP sequences were generated with the use of the
Illumina Hiseq 2000 genome analyzer. Mapped reads were
visualized in heatmaps and proﬁles using deepTools2 v2.4.0
with the UCSC hg38 refGene coordinates. QPCR of the
ARID1B region was performed with ARID1B1.1_Forward,
CGCCCACAATGTGCTTTAACGG; ARID1B1.1_Reverse,
AGGAAAAACCCACTCGCTTGTC.
Fig. 6 Direct binding of BRD2 in ARID1B locus. a The ARID1A
wildtype line OVCA429 and the ARID1A mutant line HAC2 were
cultured for 24 h in 500 nM JQ1 or DMSO vehicle control and
subjected to chromatin immunoprecipitation with BRD2 and control
antibodies. ChIP sequences were generated by Illumina Hiseq 2000
genome analyzer and aligned to the Human Reference Genome
(assembly hg38) and visualized in IGV. Displayed are IGV snap-
shots of the Transcriptional Start Sites (TSS) of the indicated SWI/
SNF members ARID1A, ARID1B, SMARCE1 and SMARCC2. b, c
Displayed are the average proﬁles of ChIP-seq signal for the
indicated cell lines in absence and presence of JQ1 at
transcriptional start site regions (+/−3 kb) (n= 66035). Shading
indicates standard error of average read count proﬁles. d, e qRT-
PCR ampliﬁcation was performed with primers located in the
ARID1B gene. Shown is the percentage of the BRD2 (d) and BRD4
(e) and control IgG chromatin immunoprecipitations over chromatin
input qRT-PCR ampliﬁcation. Error bars denote SD over n= 4 (d)
and n= 3 (e) experiments. P-values were calculated with multiple
t-tests, asterisk denote the number of digits after the decimal. Primer
location is visualized in red in the gene map displayed underneath
the graph
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Fig. 7 JQ1 speciﬁcally inhibits in vivo growth of ARID1A mutant
OCCC xenografts and PDX models. a, b ARID1A wildtype ES2 cells
(5 × 106 in PBS) were subcutaneously injected in the ﬂank of 8–10-
weeks-old NSG mice. For the ARID1A mutant SMOV2 xenograft
experiments, successfully established SMOV2 engraftments (see
methods) were dissected, and tumor pieces were subcutaneously pro-
pagated in the ﬂank of new mice. When tumors reached ~200 mm3,
mice were randomized into vehicle (DMSO) control or treatment
(JQ1) groups (n= 6 mice/group). ES2 xenografts reached the
1500 mm3 endpoint after 14 days of JQ1 administration, SMOV2
xenografts were treated with JQ1 for 21 days. c, d Displayed are the
tumorweights of the indicated excised tumors after vehicle or JQ1
treatments. e, f ARID1A wildtype (e) and mutant (f) PDX F3 tumors
were established (see methods) and tumor pieces were subcutaneously
implanted in the ﬂank of NSG mice. When tumors demonstrated
sustained growth, mice were randomized into vehicle (DMSO) control
or treatment (JQ1) groups. Treatment with JQ1 was continued for
21 days. For all in vivo experiments, JQ1 (50 mg/kg) or DMSO
vehicle were administered intraperitoneally daily and tumor growth
was quantiﬁed by caliper measurements. Tumor growth was deter-
mined as tumor volume treatment day/ tumor volume start treatment.
Statistical signiﬁcance for tumor growth was determined using two-
way ANOVA with Bonferoni post-hoc test correction. Error bars
denote standard error of mean
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OCCC xenografts and PDX models
All animal experiments were approved by the Institutional
Animal Care and Use Committee of the University of
Groningen and carried out in accordance with the approved
guidelines. For the xenografts, ES2 cells (5 × 106 in PBS)
and SMOV2 cells (5 × 106 in 50% PBS/50% Matrigel) were
subcutaneously injected in the ﬂank of 8 to 10 weeks old
NOD.CB17-Prkdcscid/NCrHsd (NSG) mice. Due to the
long latency time (on average 75 days), we used success-
fully established SMOV2 xenografts for subsequent
experiments. For this, SMOV2 xenografts were dissected,
and 3 × 3 × 3 mm3 pieces were subcutaneously propagated
in the ﬂank of new mice. STR proﬁling was used to conﬁrm
SMOV2 identity of established xenografts. Thus, ES2 cells
were injected and SMOV2 tumor pieces were transplanted
in the ﬂanks of NSG mice, and as soon as tumors reached
the threshold size of 200 mm3, mice were randomized into
vehicle control or treatment groups (n= 6 mice/group). JQ1
(50 mg/kg in 10% DMSO, 9% (2hydroxypropyl)-β-cyclo-
dextrin) or vehicle (10% DMSO, 9% (2hydroxypropyl)-β-
cyclodextrin) was daily administered intraperitoneally.
Treatment with JQ1 was continued for 21 days as described
in previous studies [28, 29]. Based on the time to reach the
humane endpoint for tumor size in mice (~1500 mm3), ES2
tumor-bearing mice had to be euthanized after 14 days of
JQ1 treatment.
OCCC PDX models were established as described pre-
viously [26]. Brieﬂy, all patients gave written informed
consent and tumor specimens were obtained during surgery.
Clinical characteristics of the patient from which ARID1A
mutant OCCC PDX was established, were FIGO stage IIIC,
no response to carboplatin/paclitaxel chemotherapy and a
9 months disease speciﬁc survival. ARID1A wildtype PDX
was established from an OCCC patient FIGO stage IIB that
showed a full response to carboplatin/paclitaxel che-
motherapy and no relapse after 13 months. OCCC PDX
models were sequenced using Haloplex (Agilent technolo-
gies) to determine ARID1A mutation status. F3 tumor pieces
from an ARID1A wildtype and ARID1A mutant PDX model
were cut into 3 × 3 × 3 mm3 pieces and subcutaneously
implanted in NSG mice. When tumors demonstrated sus-
tained growth (ARID1A wildtype PDX on average 26 days,
ARID1A mutant PDX on average 34 days), mice were
randomized into vehicle control or treatment groups (n= 5
mice/group). JQ1 (50 mg/kg in 10% DMSO, 9% (2hydro-
xypropyl)-β-cyclodextrin) or vehicle (10% DMSO, 9%
(2hydroxypropyl)-β-cyclodextrin) was daily administered
intraperitoneally. Treatment with JQ1 was continued for
21 days.
Sample size for mouse experiments were calculated to be
four mice per group (using signiﬁcance level alpha of 5%,
power 80%, estimated effect in growth reduction 50% and
coefﬁcient variation of 25%). 1–2 additional mice per group
were added in case of dropouts. Animals were excluded
when no initial tumor growth was detected before treatment
start or animals had >20% weight loss or died during
treatment course. Variances between the groups being
compared were similar.
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